A clinical study by Lubrizol has found the combination of its Argireline Amplified peptide and Botox type-A (BTA) injections can keep wrinkles at bay for nearly eight weeks longer than BTA alone.
In the recent study, 45 Caucasian volunteers, both male and female, aged between 35 and 60, received 50 UI BTA injections in the crow’s feet, frown lines, and forehead areas.
They also applied a cream containing 5% Argireline Amplified peptide solution or a placebo cream to their entire face twice daily for four months.
Researchers utilized 2D and 3D facial imaging to monitor changes in wrinkle visibility, skin roughness, and wrinkle length in areas such as crow’s feet, frown lines, and the forehead.
Results showed that after one, three and four months, participants who received the active peptide combination treatment exhibited significantly fewer wrinkles compared to those who received BTA and a placebo.
This combination treatment extended the wrinkle-free period by almost eight weeks longer than BTA alone.
“The synergy between BTA and Argireline Amplified peptide meets the growing demand for effective, longer-lasting dermo-aesthetic solutions, allowing consumers to make fewer trips to the clinic and spend more time enjoying the benefits of smooth, youthful skin,” said Lubrizol.
